Corbus Pharmaceuticals Reports $17.7 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses

Corbus Pharmaceuticals Holdings, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company recorded a net loss of approximately $17.7 million for the three months ended June 30, 2025, compared to a net loss of $10.0 million for the same period in 2024. For the six months ending June 30, 2025, the net loss was approximately $34.6 million, up from $16.9 million in the prior year. The increase in losses is attributed to heightened research and development expenses, which surged to $15.2 million in Q2 2025, a 121% increase from $6.9 million in Q2 2024.

Total operating expenses for the second quarter of 2025 reached $19.2 million, a 74% increase from $11.0 million in the same quarter of the previous year. The rise in expenses was primarily driven by increased costs associated with the company's clinical trials for its product candidates, including CRB-601, CRB-701, and CRB-913. The company’s research and development expenses for the first half of 2025 totaled $30.8 million, reflecting a 144% increase compared to $12.6 million in the first half of 2024. This increase is largely due to the ongoing clinical trials and the expansion of operational capabilities.

In terms of liquidity, Corbus reported total current assets of approximately $122.8 million as of June 30, 2025, compared to $153.0 million at the end of 2024. The company’s cash and cash equivalents increased to $20.0 million from $17.2 million during the same period. However, the accumulated deficit rose to approximately $511.5 million, indicating the ongoing financial challenges faced by the company. The company anticipates that its current cash reserves will be sufficient to meet operational needs for at least the next twelve months.

Strategically, Corbus is advancing its clinical pipeline, which includes CRB-701, CRB-601, and CRB-913, targeting oncology and obesity. The company has made progress in its clinical trials, with CRB-701 currently in a Phase 1/2 study in the U.S. and U.K., and CRB-913 having initiated its Phase 1 study. The company has also entered into several license agreements to enhance its product development capabilities, including a significant agreement with CSPC Megalith Biopharmaceutical Co. Ltd. for CRB-701.

Looking ahead, Corbus expects to continue incurring significant operating losses as it invests in the development of its product candidates. The company plans to seek additional financing through public or private equity, debt financing, or collaborations to support its ongoing operations and clinical trials. The future funding requirements will depend on market conditions and the progress of its clinical development programs, with the company acknowledging the potential risks associated with its ability to secure necessary capital.